Human NGF "Painless" Ocular Delivery for Retinitis Pigmentosa: An In Vivo Study

Area of Science:

• Ophthalmology
• Neuroscience
• Genetics

Background:

• Retinitis pigmentosa (RP) is a group of inherited retinal diseases causing progressive vision loss.
• Cone photoreceptor degeneration occurs secondary to rod cell death in RP, leading to blindness.
• Generalized biological processes like inflammation and oxidative stress contribute to cone degeneration in RP.

Purpose of the Study:

• To investigate the therapeutic potential of painless human nerve growth factor (hNGFp) in an in vivo model of retinitis pigmentosa.
• To assess hNGFp's ability to reduce retinal inflammation and provide neuroprotection.
• To evaluate the efficacy of hNGFp in preventing secondary cone degeneration in RP.

Main Methods:

• Administration of hNGFp, a TrkA receptor-biased variant of NGF with reduced p75NTR affinity, to RP-like mice.
• Evaluation of retinal inflammation and microglial cell phenotype.
• Assessment of rod and cone photoreceptor survival and overall retinal neuroprotection.

Main Results:

• hNGFp administration induced a shift in microglial cells towards a homeostatic phenotype, reducing retinal inflammation.
• The treatment provided some degree of retinal neuroprotection.
• However, hNGFp treatment showed limited efficacy in preventing the bystander degeneration of cone photoreceptors.

Conclusions:

• hNGFp demonstrates anti-inflammatory effects in the RP mouse model.
• Targeting inflammation and neurotrophic support is a potential strategy for RP therapies.
• Further research is needed to enhance the efficacy of neurotrophic factors in preventing cone degeneration in RP.